Overview
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures. In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.
Indication
Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Associated Conditions
- Edematous Fibrosclerotic Panniculopathy (Cellulite)
- Hypothyroidism
- Localized Adiposity
- Myxedema coma
- Euthyroid Goitre
- Thyrotropin dependent Well-Differentiated Thyroid Cancer
Research Report
Levothyroxine (DB00451): A Comprehensive Monograph on its Pharmacology, Clinical Use, and Evolving Therapeutic Landscape
Section 1: Foundational Characteristics of Levothyroxine
This section establishes the fundamental identity of Levothyroxine, providing the chemical and physical context necessary for understanding its pharmacological behavior.
1.1. Chemical Identity and Physicochemical Properties
Levothyroxine is a synthetically manufactured small molecule drug, identified unequivocally by its Chemical Abstracts Service (CAS) Number 51-48-9 and its DrugBank accession number DB00451.[1] It is the levorotatory (L) stereoisomer of thyroxine (T4), the primary hormone synthesized and secreted by the thyroid gland.[1] This specific stereochemistry is paramount for its biological activity and receptor binding affinity.
The molecular structure of Levothyroxine is defined by the chemical formula C15H11I4NO4, corresponding to a molecular weight of approximately 776.87 g/mol.[1] Structurally, it is a tetraiodinated derivative of the amino acid tyrosine, featuring two phenyl rings linked by an ether oxygen. Each phenyl ring is substituted with two iodine atoms, which are critical for its hormonal function.[1] The precise chemical name, reflecting its structure and stereochemistry, is (2S)-2-Amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid.[5] Reflecting its long history and widespread use in clinical and research settings, Levothyroxine is known by an extensive list of synonyms, including L-T4, 3,3',5,5'-Tetraiodo-L-thyronine, and O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine.[1]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/05/31 | Phase 3 | Not yet recruiting | |||
2025/05/14 | Not Applicable | Not yet recruiting | |||
2024/12/12 | Phase 2 | Recruiting | UConn Health | ||
2024/10/28 | Phase 3 | Completed | |||
2024/10/22 | Not Applicable | Not yet recruiting | |||
2024/10/22 | Phase 4 | Not yet recruiting | Yang ZHANG | ||
2024/10/18 | N/A | Not yet recruiting | |||
2024/10/03 | Phase 1 | Completed | |||
2024/08/09 | Phase 1 | Completed | Berlin-Chemie AG Menarini Group | ||
2024/07/30 | N/A | Terminated | Third Affiliated Hospital of Zhengzhou University |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Northwind Pharmaceuticals | 51655-696 | ORAL | 0.125 mg in 1 1 | 3/27/2023 | |
Pfizer Laboratories Div Pfizer Inc | 60793-854 | ORAL | 100 ug in 1 1 | 12/15/2020 | |
Teva Pharmaceuticals, Inc. | 0480-8715 | ORAL | 150 ug in 1 1 | 9/22/2022 | |
Northwind Pharmaceuticals | 51655-295 | ORAL | 0.1 mg in 1 1 | 1/23/2015 | |
Northwind Pharmaceuticals | 51655-124 | ORAL | 57 ug in 1 1 | 1/26/2015 | |
NuCare Pharmaceuticals,Inc. | 68071-4625 | ORAL | 75 ug in 1 1 | 4/24/2019 | |
Lupin Pharmaceuticals, Inc. | 68180-973 | ORAL | 0.15 mg in 1 1 | 3/14/2024 | |
NuCare Pharmaceuticals,Inc. | 68071-4735 | ORAL | 0.15 mg in 1 1 | 5/1/2019 | |
Acella Pharmaceuticals, LLC | 42192-328 | ORAL | 76 ug in 1 1 | 4/25/2023 | |
Camber Pharmaceuticals, Inc. | 31722-284 | ORAL | 0.025 mg in 1 1 | 1/23/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
LEVOTHYROXINE SODIUM FOR INJECTION 500 mcg/vial | SIN09760P | INJECTION, POWDER, FOR SOLUTION | 500 mcg/vial | 5/19/1998 | |
THYROCORD 50 TABLET 50 MCG | SIN16696P | TABLET | 0.05 mg | 2/15/2023 | |
EUTHYROX TABLET 50 mcg | SIN09740P | TABLET | 50 mcg | 5/6/1998 | |
ROVEXINE-75 TABLETS 75MCG | SIN16627P | TABLET | 75 mcg | 10/10/2022 | |
EUTHYROX TABLET 25 mcg | SIN09739P | TABLET | 25 mcg | 5/6/1998 | |
ROVEXINE-50 TABLETS 50MCG | SIN16628P | TABLET | 50 mcg | 10/10/2022 | |
EUTHYROX TABLET 100 mcg | SIN09741P | TABLET | 100 mcg | 5/6/1998 | |
ROVEXINE-25 TABLETS 25MCG | SIN16629P | TABLET | 25 mcg | 10/10/2022 | |
THYROCORD 75 TABLET 75 MCG | SIN16695P | TABLET | 0.075 mg | 2/15/2023 | |
THYROCORD 100 TABLET 100 MCG | SIN16694P | TABLET | 0.1 mg | 2/15/2023 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
LEVOTHYROXINE TAB 100MCG | N/A | N/A | N/A | 10/24/2011 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
ELTROXIN levothyroxine sodium 100 microgram tablet bottle | 206963 | Medicine | A | 5/19/2014 | |
LEVOTHOX levothyroxine sodium 88 microgram tablet blister | 363951 | Medicine | A | 7/25/2022 | |
LEVOTHOX levothyroxine sodium 25 microgram tablet blister | 363999 | Medicine | A | 7/25/2022 | |
THOXINE levothyroxine sodium 75 microgram tablet blister | 364020 | Medicine | A | 7/25/2022 | |
THOXINE levothyroxine sodium 100 microgram tablet bottle | 364021 | Medicine | A | 7/25/2022 | |
THOXINE levothyroxine sodium 137 microgram tablet bottle | 363993 | Medicine | A | 7/25/2022 | |
ELTROXIN levothyroxine sodium 200 microgram tablet bottle | 206954 | Medicine | A | 5/19/2014 | |
LEVOTHYROXINE SANDOZ levothyroxine sodium 200 microgram tablet blister pack | 387275 | Medicine | A | 3/21/2023 | |
LEVOTHYROXINE SANDOZ levothyroxine sodium 100 microgram tablet blister pack | 387276 | Medicine | A | 3/21/2023 | |
LEVOTHYROXINE LUP levothyroxine sodium 125 microgram un-coated tablet blister pack | 374930 | Medicine | A | 12/23/2022 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
LEVOTEC 75MCG TABLETS USP | technilab pharma inc. | 02237215 | Tablet - Oral | 75 MCG / TAB | 9/8/1998 |
ELTROXIN TAB 300MCG | glaxo canada inc | 00012319 | Tablet - Oral | .3 MG | 12/31/1966 |
ELTROXIN TAB 50MCG | glaxo canada inc | 00012289 | Tablet - Oral | 0.05 MG / TAB | 12/31/1951 |
LEVOTEC 50MCG TABLETS USP | technilab pharma inc. | 02237214 | Tablet - Oral | 50 MCG / TAB | 9/8/1998 |
APO-LEVOTHYROXINE | 02550709 | Tablet - Oral | 25 MCG | 3/17/2025 | |
SYNTHROID TAB 75MCG USP | boots pharmaceuticals ltd. | 01980971 | Tablet - Oral | 75 MCG | 12/31/1993 |
SYNTHROID | BGP Pharma ULC | 02172127 | Tablet - Oral | 150 MCG | 12/31/1996 |
SYNTHROID LIQ INJ 500MCG/VIAL USP | boots pharmaceuticals ltd. | 01981013 | Liquid - Intravenous | 500 MCG / VIAL | 12/31/1957 |
SYNTHROID TAB 175MCG USP | boots pharmaceuticals ltd. | 01980912 | Tablet - Oral | 175 MCG | 12/31/1993 |
SYNTHROID TAB 25MCG USP | boots pharmaceuticals ltd. | 01981005 | Tablet - Oral | 25 MCG | 12/31/1993 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.